A multicenter cohort study of sunitinib (SU) versus imatinib (IM) dose escalation as second-line therapy in patients with gastrointestinal stromal tumors (GISTs) after disease progression of 400 mg/d IM.

Zhang, XH; Liu, X; Wu, XJ; Pan, ZZ; Lu, HS; He, YL

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (4):